Enhancing Immunogenicity of Cancer Vaccines : QS-21 as an Immune Adjuvant
Saponins comprise a class of plant natural products that incorporate a lipophilic terpenoid core, to which is appended one or more carbohydrate residues. They are amphiphilic molecules and often exhibit toxic biological profiles, likely as a result of their roles as vital components in protective coatings to defend against phytopathogen infection and insect predation. The most notable of adjuvant-active saponins investigated for vaccine development come from the Chilean Soapbark Tree, Quillaja saponaria (i.e., QS). More than 30 years ago, semi-purified extracts (i.e., Quil A) from the cortex of Quillaja saponaria were found to be highly effective as adjuvants in veterinary vaccines. However, due to significant and variable toxicity effects, Quil A was not deemed appropriate for human vaccines. More refined purification methods have led to multiple fractions which are derived from the original plant extract. As such, QS-21 to date appears to be one of the more scientifically interesting and robust adjuvants in use in vaccinology. The role of QS-21 as an adjuvant for use in a variety of cancer vaccine trials and its comparison to other adjuvants is discussed in this review.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Current drug therapy - 6(2011), 3 vom: 08. Aug., Seite 207-212 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gin, David Y [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 30.09.2020 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM244268118 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM244268118 | ||
| 003 | DE-627 | ||
| 005 | 20231224134335.0 | ||
| 007 | tu | ||
| 008 | 231224s2011 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0814.xml |
| 035 | |a (DE-627)NLM244268118 | ||
| 035 | |a (NLM)25473385 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gin, David Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhancing Immunogenicity of Cancer Vaccines |b QS-21 as an Immune Adjuvant |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 30.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Saponins comprise a class of plant natural products that incorporate a lipophilic terpenoid core, to which is appended one or more carbohydrate residues. They are amphiphilic molecules and often exhibit toxic biological profiles, likely as a result of their roles as vital components in protective coatings to defend against phytopathogen infection and insect predation. The most notable of adjuvant-active saponins investigated for vaccine development come from the Chilean Soapbark Tree, Quillaja saponaria (i.e., QS). More than 30 years ago, semi-purified extracts (i.e., Quil A) from the cortex of Quillaja saponaria were found to be highly effective as adjuvants in veterinary vaccines. However, due to significant and variable toxicity effects, Quil A was not deemed appropriate for human vaccines. More refined purification methods have led to multiple fractions which are derived from the original plant extract. As such, QS-21 to date appears to be one of the more scientifically interesting and robust adjuvants in use in vaccinology. The role of QS-21 as an adjuvant for use in a variety of cancer vaccine trials and its comparison to other adjuvants is discussed in this review | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a QS-21 | |
| 650 | 4 | |a adjuvant | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a vaccines | |
| 700 | 1 | |a Slovin, Susan F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug therapy |d 2008 |g 6(2011), 3 vom: 08. Aug., Seite 207-212 |w (DE-627)NLM195144201 |x 1574-8855 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2011 |g number:3 |g day:08 |g month:08 |g pages:207-212 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2011 |e 3 |b 08 |c 08 |h 207-212 | ||